CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter R Smith who wrote (10)	7/27/1996 11:12:00 AM
From: John B. Anderson	of 675

To EHJE57A@prodigy.com Thanks for the information of Interneuron's drug. I did some research and it does appear that it is effective administered orally in ischemic stroke, as proven in a Phase III trial. It works by a different mechanism of action, somewhat as a TPA like clot-buster, but perhaps more importantly citicoline (IPIC's name for the drug) supplies chemicals the brain uses normally to make new brain cell membrane. As to how this impacts CNSI is a very good question, which I will pose to Ed Hurwitz. I do know that CNSI's Cerestat works by a different mechanism of action, and while I'm no neuroscientist, I believe Cerestat works by blocking the flow of calcium ions into the damaged area of the brain, where these calcium ions -- the body's emergency damage limiting mechanism -- go way beyond the necessary repair in the area of stoke or traumatic brain injury, causing massive brain cell death. Thanks again for the insight. That's the kind of help to each other this SI mechanism should promote! I'll post here the results of my conversation with Ed. John_B_Anderson@prodigy.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next